Potential association between IL-17A inhibition and blood pressure reduction in patients with axial spondyloarthritis
By
Qianqian Wu
Yifan Wang
Ting Zhao
Jie Guo
Xiaomin Zhang
Yang Tu
Feng Wang
June 22, 2026
Clinical Scorecard: Exploring the Link Between IL-17A Blockade and Blood Pressure Changes in Axial Spondyloarthritis Patients
At a Glance
Category Detail
Condition Axial Spondyloarthritis (ax-SpA) Key Mechanisms IL-17A inhibition leads to reduced inflammatory markers and improved disease activity, potentially affecting blood pressure regulation. Target Population Patients with axial spondyloarthritis, particularly those with baseline hypertension. Care Setting Rheumatology and Immunology Department
Key Highlights
IL-17A reduction in SBP and DBP in patients with axSpA. Linear mixed-effects models quantified the reduction at 0.90 and 0.91 mmHg every 4 weeks for SBP and DBP, respectively. Patients with baseline hypertension exhibited a more pronounced rate of DBP reduction. Guideline-Based Recommendations
Diagnosis
Diagnosis based on the 2009 ASAS classification criteria for ax-SpA. Management
IL-17A inhibitor Ixekizumab administered at 160 mg loading dose followed by 80 mg every 4 weeks. Monitoring & Follow-up
Monitor disease activity (ASDAS-CRP, ASDAS-ESR, BASDAI) and inflammatory markers (CRP, ESR, IL-6) at baseline and every 4 weeks. Risks
Potential cardiovascular risks associated with hypertension in axSpA patients. Patient & Prescribing Data
50 axSpA patients (30 males, 20 females; mean age 39.3 ± 15.5 years).
IL-17A inhibition was associated with significant improvements in disease activity and reductions in blood pressure.
Clinical Best Practices
Consider monitoring blood pressure in axSpA patients receiving IL-17A inhibitors. Assess for baseline hypertension to evaluate differential effects of treatment. Related Resources & Content
